Defunct Company
Total Trials
41
As Lead Sponsor
39
As Collaborator
2
Total Enrollment
8,186
NCT00006466
Beta Alethine in Treating Patients With Myeloma
Phase: Phase 1/2
Role: Lead Sponsor
Start: Aug 31, 2000
Completion: Not specified
NCT00007839
Beta Alethine in Treating Patients With Low-Grade Lymphoma
NCT00041379
Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia
Start: Mar 31, 2002
NCT00523250
Ocular Hypotensive Efficacy of AR-102
Phase: Phase 2
Start: Sep 30, 2007
Completion: Mar 31, 2008
NCT00902200
A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)
Start: May 31, 2009
Completion: Sep 30, 2009
NCT01060579
Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure
Start: Feb 28, 2010
Completion: Aug 31, 2010
NCT01250197
Formulation Comparison in Normal Volunteers
Phase: Phase 1
Start: Nov 30, 2010
Completion: Dec 31, 2010
NCT01302249
AR-12286 in Combination With Latanoprost
Start: Feb 28, 2011
Completion: Dec 31, 2011
NCT01330979
24-hour Efficacy of AR-12286
Start: May 31, 2011
Completion: Aug 31, 2012
NCT01474135
AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure
Start: Dec 31, 2011
Completion: Apr 30, 2012
NCT01528787
Study of AR-13324 in Patients With Elevated Intraocular Pressure
Start: Mar 31, 2012
Completion: Jul 31, 2012
NCT01699464
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
Start: Oct 31, 2012
Completion: Apr 30, 2013
NCT01731002
Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure
Start: Nov 30, 2012
Completion: May 31, 2013
NCT01789736
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
Start: Feb 28, 2013
Completion: Jun 30, 2013
NCT01997879
Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers
Start: Nov 30, 2013
Completion: Nov 30, 2013
NCT02057575
Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure
Start: Jan 31, 2014
Completion: Jun 30, 2014
NCT02207491
Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Phase: Phase 3
Start: Jul 31, 2014
Completion: Mar 31, 2015
NCT02207621
Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
Completion: Mar 31, 2016
NCT02246764
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Start: Sep 30, 2014
Completion: Dec 31, 2016
NCT02406287
A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers
Start: Apr 30, 2015
Completion: Apr 30, 2016
NCT02558400
Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Start: Sep 18, 2015
Completion: Jun 30, 2017
NCT02558374
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
Start: Sep 30, 2015
NCT02674854
Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
Start: Feb 29, 2016
Completion: Mar 31, 2017
NCT02874846
Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution
Start: Jul 31, 2016
Completion: Sep 30, 2016
NCT03284853
Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension
Start: Sep 5, 2017
Completion: Nov 6, 2020
NCT03233308
Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Start: Oct 20, 2017
Completion: Apr 19, 2018
NCT03310580
Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension
Start: Nov 15, 2017
Completion: Oct 25, 2018
NCT03808688
Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting
Phase: Phase 4
Start: Dec 27, 2018
Completion: Jul 26, 2019
NCT03739593
Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
Start: Mar 13, 2019
Completion: Jul 9, 2020
NCT03844945
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Start: Mar 19, 2019
Completion: Sep 19, 2019
NCT03835884
A Study Assessing AR-13503 Implant in Subjects With nAMD or DME
Start: Jun 24, 2019
Completion: May 12, 2022
NCT04498169
A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy
Start: Sep 17, 2020
Completion: Aug 11, 2021
NCT04498182
A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease
Start: Oct 26, 2020
Completion: Jul 17, 2021
NCT04620135
Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Start: Nov 30, 2020
Completion: Jul 30, 2021
NCT04401982
Measuring the Effects of Rhopressa on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects
Phase: N/A
Role: Collaborator
Start: Mar 15, 2021
Completion: Feb 22, 2022
NCT05497479
Study Evaluating Techniques for Measuring Tear Production
Start: Dec 9, 2021
Completion: Dec 10, 2021
NCT04064918
Effects of Netarsudil and Timolol on Retinal Blood Vessel Density and Visual Acuity
Start: Dec 31, 2021
Completion: Jan 31, 2023
NCT05283395
Rocklatan® Evaluation
Start: Mar 28, 2022
Completion: Mar 22, 2023
NCT05285644
Study Evaluating the Safety and Efficacy of AR-15512
Start: May 9, 2022
Completion: Jul 24, 2023
NCT05360966
Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)
Start: Jul 18, 2022
Completion: Oct 17, 2023
NCT05493111
A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512
Start: Nov 1, 2022
Completion: Feb 28, 2024